Harold Eugene Brakewood
CIK: 0001969578
Transaction Breakdown
Open Market Buys (P)2 (50.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
IMRX
Immuneering Corp
Officer
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Feb 3, 2026IMRX
Immuneering Corp
Award(A)DirectStock Option
140K shares- - Jan 16, 2026IMRX
Immuneering Corp
Purchase(P)Direct5.3K shares at avg. $4.76$25K - Jun 20, 2025IMRX
Immuneering Corp
Purchase(P)Direct1.9K shares at avg. $2.53$5K - Feb 5, 2025IMRX
Immuneering Corp
Award(A)DirectStock Option
100K shares-
1-4 of 4 transactions
About Brakewood Harold Eugene
Brakewood Harold Eugene (SEC CIK 0001969578) files insider reports with the SEC as Chief Business Officer of Immuneering Corp (IMRX).
Signal8 holds 4 ownership filings by Brakewood Harold Eugene, all Form 4s, filed between Feb 7, 2025 and Feb 5, 2026. Those filings report 4 transactions, from Feb 5, 2025 to Feb 3, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Brakewood Harold Eugene's filings is in CAMBRIDGE, MA.
Recent filings by Brakewood Harold Eugene
Other insiders filing for Immuneering Corp (IMRX)
- Gengos Andrew, Chief Financial Officer
- Zeskind Benjamin J., PRESIDENT AND CEO
- Hall Brett Matthew, CHIEF SCIENTIFIC OFFICER
- Schall Thomas J., Director
- HAUSMAN DIANA, Director
- CARPENTER ROBERT J, Director